选择性凋亡标志物和粘附分子对慢性淋巴细胞白血病治疗效果的影响

Thoraya Abdelhamid, Amira Khorshed, Nahed Abdelwahab, Hesham Shahin, Dhalia Khadry, Gehan Abdel Wahab, Nahla Elsharkawy, Nevein Alazhary
{"title":"选择性凋亡标志物和粘附分子对慢性淋巴细胞白血病治疗效果的影响","authors":"Thoraya Abdelhamid,&nbsp;Amira Khorshed,&nbsp;Nahed Abdelwahab,&nbsp;Hesham Shahin,&nbsp;Dhalia Khadry,&nbsp;Gehan Abdel Wahab,&nbsp;Nahla Elsharkawy,&nbsp;Nevein Alazhary","doi":"10.3816/CLM.2009.n.097","DOIUrl":null,"url":null,"abstract":"<div><p>We assessed the impact of selected apoptotic markers and adhesion molecules on the treatment outcome. Thirty newly diagnosed patients and 10 healthy subjects were studied. Proapoptotic markers (BCL2, p53, and CD95) and adhesion molecules (CD18, CD54) were assessed by flow cytometry before and after treatment. p21 mRNA was assessed by RT-PCR. Induction was done with the CVP regimen.</p></div><div><h3>Full Abstract</h3><p>The study included 23 men and 7 women. Median age was 66 years (range, 53-79 years). There were increases of p53 and BCL2 and reductions of CD18 and CD54 in cases compared to control. CD95 did not show significant increase compared to control. There were reductions in BCL2 after (versus before) treatment and increases in CD18 and CD54 after (versus before) treatment. Evaluable patients showed 11 complete remission (CRs; 39.3%), 7 (25%) partial remissions, 6 progressive diseases (21.4%), and 4 stable diseases (14.3%). The observation after treatment was 2 to 13 months. Median time to disease progression (TTP) of the responding patients was 9 months. Death was reported in 1 case. There was an increase in p53 and BCL2 expression in patients who did not achieve CR compared to those with CR and an increase in CD18 level in CR more than no-CR cases. No significant differences were found regarding the expression of CD95 and CD54 between both groups. Comparing the level of expression of the studied markers at initial presentation, there were increases in p53 and decreases in CD18 level in patients with no CR compared to those with CR. There was positive correlation between the expression of p53 and BCL2 and negative correlation between the p53 and CD18 and between BCL2 and CD18. There was significant negative correlation between TTP and BCL2 levels after treatment. Selected cases for p21 mRNA assessment showed negative correlation between p21 mRNA and p53 levels before treatment and decrease in p21 level was associated with poor prognosis and bad response to treatment. In conclusion, measurement of p53 and CD18 level can define a group of patients with aggressive disease who may require more aggressive therapy. BCL2 level after treatment is correlated with TTP.</p></div><div><h3>Acknowledgment</h3><p>The study was conducted at NCI-Cairo between 2004 and 2007.</p></div>","PeriodicalId":100272,"journal":{"name":"Clinical Lymphoma and Myeloma","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CLM.2009.n.097","citationCount":"0","resultStr":"{\"title\":\"The Impact of Selected Apoptotic Markers and Adhesion Molecules on the Treatment Outcome of Chronic Lymphocytic Leukemia\",\"authors\":\"Thoraya Abdelhamid,&nbsp;Amira Khorshed,&nbsp;Nahed Abdelwahab,&nbsp;Hesham Shahin,&nbsp;Dhalia Khadry,&nbsp;Gehan Abdel Wahab,&nbsp;Nahla Elsharkawy,&nbsp;Nevein Alazhary\",\"doi\":\"10.3816/CLM.2009.n.097\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>We assessed the impact of selected apoptotic markers and adhesion molecules on the treatment outcome. Thirty newly diagnosed patients and 10 healthy subjects were studied. Proapoptotic markers (BCL2, p53, and CD95) and adhesion molecules (CD18, CD54) were assessed by flow cytometry before and after treatment. p21 mRNA was assessed by RT-PCR. Induction was done with the CVP regimen.</p></div><div><h3>Full Abstract</h3><p>The study included 23 men and 7 women. Median age was 66 years (range, 53-79 years). There were increases of p53 and BCL2 and reductions of CD18 and CD54 in cases compared to control. CD95 did not show significant increase compared to control. There were reductions in BCL2 after (versus before) treatment and increases in CD18 and CD54 after (versus before) treatment. Evaluable patients showed 11 complete remission (CRs; 39.3%), 7 (25%) partial remissions, 6 progressive diseases (21.4%), and 4 stable diseases (14.3%). The observation after treatment was 2 to 13 months. Median time to disease progression (TTP) of the responding patients was 9 months. Death was reported in 1 case. There was an increase in p53 and BCL2 expression in patients who did not achieve CR compared to those with CR and an increase in CD18 level in CR more than no-CR cases. No significant differences were found regarding the expression of CD95 and CD54 between both groups. Comparing the level of expression of the studied markers at initial presentation, there were increases in p53 and decreases in CD18 level in patients with no CR compared to those with CR. There was positive correlation between the expression of p53 and BCL2 and negative correlation between the p53 and CD18 and between BCL2 and CD18. There was significant negative correlation between TTP and BCL2 levels after treatment. Selected cases for p21 mRNA assessment showed negative correlation between p21 mRNA and p53 levels before treatment and decrease in p21 level was associated with poor prognosis and bad response to treatment. In conclusion, measurement of p53 and CD18 level can define a group of patients with aggressive disease who may require more aggressive therapy. BCL2 level after treatment is correlated with TTP.</p></div><div><h3>Acknowledgment</h3><p>The study was conducted at NCI-Cairo between 2004 and 2007.</p></div>\",\"PeriodicalId\":100272,\"journal\":{\"name\":\"Clinical Lymphoma and Myeloma\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.3816/CLM.2009.n.097\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lymphoma and Myeloma\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1557919011700488\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma and Myeloma","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1557919011700488","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

我们评估了选定的凋亡标记物和粘附分子对治疗结果的影响。研究对象为30例新确诊患者和10例健康受试者。采用流式细胞术检测治疗前后细胞凋亡标志物(BCL2、p53、CD95)和粘附分子(CD18、CD54)。RT-PCR检测p21 mRNA表达。诱导采用CVP方案。该研究包括23名男性和7名女性。中位年龄66岁(53-79岁)。与对照组相比,病例中p53和BCL2升高,CD18和CD54降低。与对照组相比,CD95没有明显增加。治疗后(与治疗前相比)BCL2降低,治疗后(与治疗前相比)CD18和CD54升高。可评估的患者有11例完全缓解(cr);39.3%),部分缓解7例(25%),进展性疾病6例(21.4%),稳定性疾病4例(14.3%)。治疗后观察2 ~ 13个月。应答患者到疾病进展的中位时间(TTP)为9个月。报告1例死亡。与CR患者相比,未达到CR患者的p53和BCL2表达增加,CR患者的CD18水平高于无CR患者。两组间CD95和CD54的表达差异无统计学意义。比较首发时所研究标记物的表达水平,无CR患者与有CR患者相比,p53水平升高,CD18水平降低,p53与BCL2表达呈正相关,而p53与CD18、BCL2与CD18表达呈负相关。治疗后TTP与BCL2水平呈显著负相关。选定的p21 mRNA评估病例显示,治疗前p21 mRNA与p53水平呈负相关,p21水平下降与预后差和治疗反应差有关。总之,测量p53和CD18水平可以确定一组可能需要更积极治疗的侵袭性疾病患者。治疗后BCL2水平与TTP相关。本研究于2004年至2007年在NCI-Cairo进行。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Impact of Selected Apoptotic Markers and Adhesion Molecules on the Treatment Outcome of Chronic Lymphocytic Leukemia

We assessed the impact of selected apoptotic markers and adhesion molecules on the treatment outcome. Thirty newly diagnosed patients and 10 healthy subjects were studied. Proapoptotic markers (BCL2, p53, and CD95) and adhesion molecules (CD18, CD54) were assessed by flow cytometry before and after treatment. p21 mRNA was assessed by RT-PCR. Induction was done with the CVP regimen.

Full Abstract

The study included 23 men and 7 women. Median age was 66 years (range, 53-79 years). There were increases of p53 and BCL2 and reductions of CD18 and CD54 in cases compared to control. CD95 did not show significant increase compared to control. There were reductions in BCL2 after (versus before) treatment and increases in CD18 and CD54 after (versus before) treatment. Evaluable patients showed 11 complete remission (CRs; 39.3%), 7 (25%) partial remissions, 6 progressive diseases (21.4%), and 4 stable diseases (14.3%). The observation after treatment was 2 to 13 months. Median time to disease progression (TTP) of the responding patients was 9 months. Death was reported in 1 case. There was an increase in p53 and BCL2 expression in patients who did not achieve CR compared to those with CR and an increase in CD18 level in CR more than no-CR cases. No significant differences were found regarding the expression of CD95 and CD54 between both groups. Comparing the level of expression of the studied markers at initial presentation, there were increases in p53 and decreases in CD18 level in patients with no CR compared to those with CR. There was positive correlation between the expression of p53 and BCL2 and negative correlation between the p53 and CD18 and between BCL2 and CD18. There was significant negative correlation between TTP and BCL2 levels after treatment. Selected cases for p21 mRNA assessment showed negative correlation between p21 mRNA and p53 levels before treatment and decrease in p21 level was associated with poor prognosis and bad response to treatment. In conclusion, measurement of p53 and CD18 level can define a group of patients with aggressive disease who may require more aggressive therapy. BCL2 level after treatment is correlated with TTP.

Acknowledgment

The study was conducted at NCI-Cairo between 2004 and 2007.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信